Form D · Other Health Care

Precision Neuroscience Corp

New York, NY · CIK 0001858288

Offering snapshot reported Sep 28, 2026 · SEC filing

Reported sold
$250M
Indefinite offering
Investors reported
46
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Sep 11, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Sep 28, 2026Initial$249,999,984No comparison46SEC filing
Oct 17, 2024Initial$93,118,915No comparison21SEC filing
Apr 2, 2024Initial$27,500,000No comparison5SEC filing
Feb 1, 2023Amendment$41,150,023$6,850,005vs Dec 19, 202220SEC filing
Dec 19, 2022Initial$34,300,018No comparison15SEC filing
Apr 28, 2021Initial$10,500,000No comparisonNot reportedSEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0 (estimated)
Finders' fees
$0
Form D file number
021-599075

Source: Form D, filed Sep 28, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Konstantinos Alataris Director, Executive
Eric M. Attias Director
Stephen Biggar Director
Jason Chen Director
Michael Goller Director
Mike Kaswan Executive
Michael Kaswan Executive
M Ichael Kaswan Executive
Michael Mager Director, Executive
Ravi Mehta Director
Craig Mermel Director, Executive
Howard Morgan Director
Benjamin Rapoport Director, Executive

Issuer details

Industry: Other Health Care (See others in industry)

Address:
54 W 21st St. Suite 301
New York, NY, 10010